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The lymphocytic ionotropic purinergic P2X receptors (P2X1R-
P2X7R, or P2XRs) sense ATP released during cell damage-
activation, thus regulating T-cell activation. We aim to deﬁne
the role of P2XRs during islet allograft rejection and to establish
a novel anti-P2XRs strategy to achieve long-term islet allograft
function. Our data demonstrate that P2X1R and P2X7R are in-
duced in islet allograft-inﬁltrating cells, that only P2X7R is
increasingly expressed during alloimmune response, and that
P2X1R is augmented in both allogeneic and syngeneic trans-
plantation. In vivo short-term P2X7R targeting (using periodate-
oxidized ATP [oATP]) delays islet allograft rejection, reduces the
frequency of Th1/Th17 cells, and induces hyporesponsiveness
toward donor antigens. oATP-treated mice displayed preserved
islet grafts with reduced Th1 transcripts. P2X7R targeting and
rapamycin synergized in inducing long-term islet function in 80%
of transplanted mice and resulted in reshaping of the recipient
immune system. In vitro P2X7R targeting using oATP reduced
T-cell activation and diminished Th1/Th17 cytokine production.
Peripheral blood mononuclear cells obtained from long-term
islet-transplanted patients showed an increased percentage of
P2X7R
+CD4
+ T cells compared with controls. The beneﬁcial
effects of oATP treatment revealed a role for the purinergic sys-
tem in islet allograft rejection, and the targeting of P2X7R is
a novel strategy to induce long-term islet allograft function.
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T
he current mainstay of treatment for type 1
diabetes (T1D) is insulin therapy, which has
proven to be a lifesaving breakthrough. How-
ever, insulin treatment cannot fully prevent the
severe complications related to the disease, including
kidney failure and coronary heart disease (1,2). Successful
islet transplantation cures T1D, improves glycometabolic
control, reduces hypoglycemic episodes, and halts di-
abetes complications (3–5). Unfortunately, the rate of
functioning islet allografts at 5 years is well below 20%
(6), primarily, although not exclusively, due to alloreactive
and autoreactive immune responses (7–9). The anti-islet
immune response involves a complex interplay between
pathogenic and inﬂammatory immune pathways, which
promote rejection, and regulatory or anti-inﬂammatory
immune pathways, which facilitate tolerance toward
transplants (10–12); one such pathway is the purinergic
system (13).
The purine ATP is a small molecule (14) present at high
concentrations within cells and released after cell damage
or death (15) and immune cell activation (16,17); it acts as
a danger signal and potent chemotactic mediator (15,18).
ATP is abundant at inﬂammation sites and is sensed by
ionotropic purinergic P2X receptors (seven receptors
named P2X1-P2X7, or P2XRs) (19–21). In leukocytes,
P2XRs regulate cytokine production, activation, and apo-
ptosis (thus constituting an “autocrine alerting system”)
(13,22–24). In particular, P2X7R (16,21,25,26) has been
linked to T-cell activation and function, serving as a signal
ampliﬁcation mechanism for antigen recognition (13).
Recent studies have shown that ATP may be a factor that
determines the fate of T cells by promoting Th17 differ-
entiation (24), and Th17 cells have been demonstrated to
be relevant in islet allograft rejection (27–29). Inhibiting
P2X7R halts the delivery of ATP signals and may redirect
the immune system from a Th1/Th17 proﬁle to a more
tolerogenic state (30). P2X7R inhibitors are available for
human use, including periodate-oxidized ATP (oATP) and
CE-224535, thereby rendering P2X7R targeting a potential
path to be tested in transplantation. Of particular interest
is oATP, a small Schiff-base molecule that irreversibly
antagonizes P2X7R through the selective modiﬁcation of
lysine residues in the vicinity of the ATP-binding site (31,32).
We explored the role of P2X7R in islet allograft rejection as
a means of establishing an anti–P2X7R-based strategy to
redirect the immune system toward a more tolerogenic
proﬁle and thus achieving stable tolerance to islet allografts.
RESEARCH DESIGN AND METHODS
Patients. Peripheral blood mononuclear cell (PBMC) fractions were isolated
by Ficoll (GE Healthcare, Piscataway, NJ) from patients with T1D (n = 8) and
patients who had received allogeneic islet transplantation ,3 (n = 8) or .3
(n = 8) years earlier, as well as healthy control patients (n = 8). Patient
characteristics are presented in Table 1.
Human islet transplantation and immunosuppression. Islet-transplanted
patients received the standard triple immunosuppressive regimen: anti-
Thymoglobulin (Fresenius, Waltham, MA), followed by FK506 (target blood
levels, 6–8 ng/mL; Astellas, Deerﬁeld, IL) and/or cyclosporine (100 ng/mL;
Novartis, Basel, Switzerland) and/or rapamycin (8–15 ng/mL; Pﬁzer, New York,
NY) and/or mycophenolate (2 g/day; Roche, Basel, Switzerland) and predni-
sone (5–10 mg/day; Bruno Farmaceutici, Rome, Italy) (33).
Mice. C57BL/6, BALB/c, and C57BL/6 P2X7R
2/2 mice were obtained from the
Jackson Laboratory, Bar Harbor, Maine. All mice were cared for and used in
accordance with institutional guidelines approved by the Harvard Medical
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Murine islet transplantation. Pancreatic islets were isolated (34) and
transplanted under the renal capsule of mice rendered diabetic with strepto-
zotocin (225 mg/kg, administered i.p.; Sigma Aldrich, St. Louis, MO). Rejection
was deﬁned as blood glucose levels .250 mg/dL for 2 consecutive days.
Interventional studies. Mice were injected intraperitoneally with 1) oATP
(Medestea Srl, Turin, Italy) at 250 mg/day for 14 days, 2) rapamycin (LC
Laboratories, Woburn, MA) at 0.1 mg/day for 10 days, or 3) oATP+rapamycin
at the combination of 1 and 2. oATP, Benzoyl-ATP (Sigma-Aldrich), NF449
(P2X1R antagonist), and NF110 (P2X3R antagonist; Tocris, Minneapolis, MN)
were used in in vitro assays. CE-224535 was provided by Pﬁzer.
Histology and immunohistochemistry. Immunohistochemistry was per-
formed on formalin-ﬁxed, parafﬁn-embedded tissue (34). Photomicrographs
(original magniﬁcation 340) were taken using an Olympus BX41 microscope
(Center Valley, PA). The antibodies used were anti-CD3 (Cell Marque, Rocklin,
CA), anti-FoxP3 (eBioscience, San Diego, CA), anti-insulin (Dako North
America, Carpinteria, CA), anti-glucagon (Abcam, Cambridge, UK), anti-Mac2
(Euroclone, Milan, Italy), and anti-P2X7 (Alomone Laboratories, Jerusalem,
Israel). Histology was evaluated by an expert pathologist.
Quantitative real-time PCR. Total RNA was extracted from immune cells or
isletgrafts.ForisletgraftsRNAisolation,thekidneycapsulewasdetachedfrom
the kidney, and the graft attached to the capsule was excised, thus minimizing
contamination from parenchymal tissue. RNA was puriﬁed from the tissue
using an RNeasy kit (Qiagen, Valencia, CA), and homogenization was per-
formed using a rotor-stator homogenizer. RNA was reverse-transcribed into
cDNA using Superscript III (Invitrogen, Carlsbad, CA). Transcripts were
ampliﬁed using a 7300 Real-Time PCR System and analyzed by the DDCT
method, and GAPDH was used as the internal reference (35). Primers were
obtained from Applied Biosystems (Foster City, CA), in particular, P2X1R
(Mm00435460_m1), P2X2R (Mm01202368_g1), P2X3R (Mm00523699_m), P2X4R
(Mm00501787_m1), P2X5R (Mm00473677_m1), P2X6R (Mm00440591_m1), and
P2X7R (Mm00440578_m1).
Insulin and glucagon quantiﬁcation. Collected tissue was homogenized in
ethanol. Islet content was extracted after two cycles of incubation with 85%
phosphoric acid (Mallinckrodt, Paris, KY) at a pH of 1.8 to 2.0 (36). Super-
natants were collected and stored at 280°C until assayed for insulin content
by ELISA (Mercodia, Winston Salem, NC) and for glucagon by Luminex
technology (Millipore, Billerica, MA).
Enzyme-linked immunosorbent spot assay. An enzyme-linked immunosor-
bent spot (ELISPOT) assay was used to measure the number of cells producing
interferon (INF)-g/interleukin (IL)-4 according to the manufacturer’sp r o t o c o l
(BD Biosciences, San Jose, CA) (37). Spots were counted using an Immunospot
analyzer (Cellular Technology Ltd, Cleveland, OH).
Flow cytometry and intracellular cytokine staining. Anti-mouse/anti-
human CD3, CD4, CD45RO, CD45RA, CD8, CD25, CD44, CD62L, IL-17, annexin
V, 7-amino-actinomycin D, and FoxP3 were purchased from BD Biosciences
and eBioscience. Anti-P2X7R was purchased from Alomone Laboratories (38).
Mixed lymphocyte reaction. BALB/c splenocytes were used after irradiation
with 3,000 rads to stimulate C57BL/6 splenocytes at a ratio of 1:1. Proliferation
was measured after 3 days following pulsing with
[3H]TdR (Perkin Elmer,
Wellesley, MA), and cell counts were quantiﬁed using a liquid scintillation
counter.
Luminex assays. Serum was collected from treated or control mice and an-
alyzed using the Beadlyte Mouse Multi-Cytokine Beadmaster Kit (Millipore,
Billerica, MA).
ATP level determination. Bioluminescent detection of ATP levels was per-
formed in serum samples using the Enliten ATP assay system (FF2000,
Promega Corporation, Madison, WI).
Statistical analysis. Data are expressed as mean 6 SEM. Kaplan-Meier
analysis was used for analysis of survival. When two groups were compared,
a two-sided unpaired Student t test (for parametric data) or a Mann-Whitney
test (for nonparametric data) was used. A P value , 0.05 (by two-tailed
testing) was considered an indicator of statistical signiﬁcance. Graphs were
generated using GraphPad Prism 5.0 software (GraphPad Software, San
Diego, CA).
RESULTS
P2X7R is speciﬁcally expressed in islet allograft-
inﬁltrating lymphocytes during the alloimmune
response in vivo. We ﬁrst evaluated the expression of
P2XR mRNA during the alloimmune response in vivo in
an islet transplantation model. BALB/c (H-2
d) islets were
transplanted under the kidney capsule of C57BL/6 (H-2
b)
mice, rendered diabetic through streptozotocin, and
islet allografts and spleens were harvested at day 14,
according to the kinetics of islet allograft rejection (39).
P2XR expression levels were compared with baseline val-
ues using untransplanted BALB/c islets or naïve C57BL/6
splenocytes. A signiﬁcantly higher expression of P2X1R
(10-fold increase vs. baseline, n =3 ;P = 0.0002) and P2X7R
(10-fold increase vs. baseline, n =3 ;P = 0.01) was evident
in the graft (Fig. 1A). No changes were observed in the
expression of the remaining P2XRs in the graft (Fig. 1A)o r
in any P2XR in the spleen (data not shown).
To explore the possible effects of ischemia/reperfusion
injury and peritransplant inﬂammation on P2XR expres-
sion levels, we evaluated P2XR expression in the setting
of syngeneic islet transplantation—C57BL/6 islets into
hyperglycemic C57BL/6 mice—in which the effects of the
alloimmune response are absent. At day 14 after trans-
plantation, P2X1R expression was increased in the synge-
neic graft compared with baseline (14-fold increase, n =3 ;
P = 0.008), similarly to what we observed in allogeneic
TABLE 1
Characteristics of islet-transplanted patients and healthy volunteers
Islet-transplanted patients
Healthy volunteers
(n =8 )
T1D patients
(n =8 )
Short-term
(n =8 )
Long-term
(n =8 )
Sex (n)
Male 4 4 4 5
Female 4 4 4 4
Age (years) 42.3 6 3.3 39 6 5 43.7 6 6.0 48.5 6 5
T1D (years) — 25 6 10 29.0 6 9.1 31.3 6 3.5
Time since last islet infusion (years) —— 1.2 6 0.5 7.0 6 1.2
C-peptide (ng/mL) — 0.01 6 0.3 1.9 6 1 1.7 6 0.8
Exogenous insulin requirement (units/day) — 32 6 3.2 7.2 6 1 6.7 6 3
HbA1c (%) — 8.8 6 1.5 6.8 6 1.1 5.6 6 2.4
Rapamycin + FK506 (n) —— 23
FK506 + mycophenolate (n) —— 33
Cyclosporine + mycophenolate (n) —— — 1
Rapamycin + mycophenolate (n) —— 3 —
Rapamycin + azathioprine (n) —— — 1
Continuous data are expressed as mean 6 SD. HbA1c, glycated hemoglobin.
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NS; Fig. 1A); these data suggest that P2X1R expression is
related more to ischemia/reperfusion injury and peri-
transplant inﬂammation than to the allogeneic response.
Conversely, P2X7R expression did not signiﬁcantly in-
crease in syngeneic grafts (n =3 ;P = NS vs. baseline), thus
suggesting that P2X7R expression is speciﬁcally increased
during alloimmunity (syngeneic day 14 vs. allogeneic day
14, n =3 ;P = 0.04; Fig. 1A).
We then used immunostaining to assess which cell-type
was responsible for the higher expression of P2X7R ob-
served. P2X7R-positive staining was observed in the mono-
nuclear cell inﬁltrate at day 14 after transplantation, with no
P2X7R expression in kidney structures or islet parenchymal
cells (Fig. 1B and C). ATP levels in the serum were stable
over the course of islet transplantation (data not shown).
Targeting P2X7R in vivo prolongs islet allograft
survival. We next used oATP to test the effect of P2X7R
targeting in the allogeneic islet transplantation model. oATP
has been shown to irreversibly antagonize P2X7R through
t h es e l e c t i v em o d i ﬁcation of lysine residues in the vicinity of
the ATP-binding site and may also exert additional immu-
nomodulatory effects through the modulation of the other
purinergic receptors (31,32). Untreated mice invariably
rejected islet transplants within 14 days (mean survival time
[MST] = 12 days, n = 10; Fig. 2A); conversely, mice treated
daily with oATP (250 mgi . p . )f o r1 4d a y sd i s p l a y e das i g n i f -
icant delay in islet rejection (MST = 22 days, n =1 0 ;P ,
0.0001 vs. untreated), and 3 of 10 mice showed long-term
graft function at 100 days after transplantation (Fig. 2A).
Targeting P2X7R in vivo reduces the severity of the
alloimmune response. We performed immune proﬁling
of islet-transplanted oATP-treated and untreated mice at
day 14 after transplantation. When splenocytes harvested
from oATP-treated recipients were challenged with donor-
derived splenocytes, a reduction was observed at day 14 in
the number of cells producing IFN-g (oATP-treated = 117 6
9 vs. untreated = 418 6 26, n =5 ;P , 0.0001; Fig. 2B), with
no effect on the number of cells producing IL-4 (Fig. 2C).
No signiﬁcant changes in the percentages of peripheral
CD4
+ T effector cells were observed between groups
(CD44
highCD62L
lowCD4
+ T cells; Fig. 2D). Slight reduc-
tions were evident in the percentages of CD8
+ T effector
cells (Fig. 2E) and of Th17 cells (Fig. 2F). No differences
were observed in the percentages of regulatory T-cells
(CD25
+FoxP3
+CD4
+ T-cells, or Tregs; Fig. 2G). The cytokine
proﬁle of sera showed that IL-6, a Th17 cytokine, was re-
duced in oATP-treated recipients (Fig. 2K), whereas only
minor changes were observed for all other cytokines ex-
amined (Fig. 2H–J, L and M).
Targeting P2X7R in vivo reduces inﬁltration and Th1
transcripts in islet allografts. We next analyzed the
pathology of islet allografts 14 days after transplantation.
Islet structure was substantially compromised, and insulin
or glucagon staining were undetectable in untreated mice
(Fig. 3A, E and F, respectively), with diffuse inﬁltration
primarily constituted by CD3
+ T cells and MAC2
+ macro-
phages, with very few FoxP3
+ cells (Fig. 3A–D). Con-
versely, islet structure and insulin and glucagon staining
were maintained in oATP-treated mice (Fig. 3G, K and L,
respectively), with inﬁltrate mainly conﬁned to the islet
borders with several FoxP3
+ cells (Fig. 3G–J). Semi-
quantitative analysis conﬁrmed preserved insulin staining
at day 14 in oATP-treated mice but not in the untreated
mice (Fig. 3M), with no major differences in the overall
inﬁltrate (Fig. 3N). A reduction in the mRNA expression of
FIG. 1. Allogeneic (BALB/c) or syngeneic (C57BL/6) islets were transplanted into diabetic C57BL/6 recipient mice and harvested at day 14 after
transplantation. P2XR mRNA levels were compared with untransplanted BALB/c islets (Baseline). A: Higher P2X1R expression was evident in
syngeneic and allogeneic transplanted islets compared with baseline (n =3 ,* * P < 0.01), whereas higher expression of P2X7R was observed
speciﬁcally in the allogeneic graft (n =3 ;* P < 0.05). Immunohistochemical analysis showed positive staining for P2X7 in inﬁltrating mononuclear
cells with absence of staining in islet and kidney parenchymal cells by hematoxylin and eosin (H&E) (B) and P2X7R (C).
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decrease, n =3 ;P = 0.02 vs. untreated; Fig. 3O), but not
in Rorc, a marker of the Th17 immune response (Fig. 3P),
was observed in the graft inﬁltrate of oATP-treated mice.
Further analysis of the insulin and glucagon content in
the transplanted islets conﬁrmed the graft protection
conferred by oATP treatment at day 14 (insulin content:
untreated = 2.3 6 0.4 mg/L vs. oATP-treated = 3,698 6
843 mg/L, n = 5 and 10; P = 0.009; Fig. 3Q; glucagon con-
tent: untreated = undetectable vs. oATP-treated = 32,999 6
18,657 pmol/L, n = 5 and 6; P = 0.007; Fig. 3R).
Targeting P2X7R in vitro reduces the severity of the
alloimmune response. To conﬁrm the data we obtained
in vivo, we evaluated the effect of targeting P2X7R in vitro
using alloimmune-relevant assays. Responder splenocytes
from C57BL/6 mice were challenged with irradiated stimu-
lator splenocytes from BALB/c mice. The numbers of cells
producing IFN-g and IL-4 were evaluated in an ELISPOT
assay in the presence of increasing concentrations of
oATP. P2X7R targeting robustly inhibited IFN-g produc-
tion (cells producing IFN-g: oATP 100 mmol/L = 30 6 2 vs.
control = 190 6 4, n =5 ;P , 0.0001; Fig. 4A), but a dose-
dependent increase in IL-4 production was observed
(Fig. 4B). To conﬁrm in vitro suppression of the alloan-
tigen response, we performed a mixed leukocyte reaction
experiment in which alloantigen-mediated cell prolifera-
tion appeared to be suppressed (number of proliferating
c e l l sa sm e a s u r e db y
3H-thymidine incorporation: oATP
100 mmol/L = 136 6 5 vs. control = 6,199 6 498, n =5 ;
P , 0.0001; Fig. 4C). C57BL/6 splenocytes were also
challenged with allogeneic cells in the presence of oATP
(100 mmol/L) for 24 h, and apoptosis was assessed by
ﬂuorescence-activated cell sorter as the percentage of
annexin V
+7AAD
2 cells; no increase in the percentage of
apoptotic cells was detected (Fig. 4D).
We then tested the effect of increasing doses of oATP
on Th1/Th17 cytokine levels. A dose-dependent response
was evident, in which oATP reduced the number of cells
producing Th1 cytokines (IFN-g and IL-2) and Th17
cytokines (IL-6 and IL-17; Fig. 4E–H). Because it has been
reported that oATP may affect other P2XRs, we made use
of the availability of the selective P2X1R inhibitor NF 449
and of the selective P2X3R inhibitor NF 110. C57BL/6
splenocytes were stimulated with irradiated BALB/c
splenocytes, and IFN-g production was evaluated in the
presence of these inhibitors. P2X1R and P2X3R inhibition
failed to modulate alloantigen-mediated IFN-g production
(Fig. 4I and J); these data conﬁrmed the marginal role of
P2X1R and P2X3R in the alloimmune response, at least in
vitro.
Genetic targeting of P2X7R slightly prolongs islet
graft survival. We also determined the effect of genetic
targeting of P2X7R on islet graft survival. P2X7R
2/2
C57BL6 mice were transplanted with allogeneic BALB/c
islets, and partial prolongation of graft survival was ob-
served compared with wild-type recipients (MST: P2X7R
2/2
= 19 days, n = 10; P , 0.0001 vs. wild-type; Fig. 5A). oATP
treatment on P2X7R
2/2 recipients was able to further
FIG. 2. The effect of P2X7R-targeting using oATP was tested in a model of allogeneic BALB/c islet transplantation into hyperglycemic C57BL/6
mice. A: Signiﬁcant prolongation of graft survival was shown in oATP-treated compared with untreated mice (n = 10; ***P < 0.0001). Splenocytes
obtained from oATP-treated mice displayed fewer numbers of cells producing IFN-g compared with untreated mice when challenged with irra-
diated donor splenocytes (n = 5, ***P < 0.0001 vs. untreated at day 14) (B), whereas the number of cells producing IL-4 did not differ between the
two groups (C). The percentages of CD4
+ T effector (D) and Tregs were unchanged (G) at day 14 in the splenocyte population of oATP-treated
islet-transplanted mice compared with untreated mice, whereas the percentages of CD8
+ effector T-cells (n = 5, ***P < 0.0001 vs. untreated day
14) (E) and Th17 cells (n =5 ,* P < 0.05 vs. untreated at day 14) (F) were reduced. IL-6 peripheral levels, but not levels of IFN-g (H), IL-4 (I), IL-5
(J), IL-10 (L), or IL-17 (M), were reduced in oATP-treated mice compared with untreated mice (n =5 ,* * P < 0.01 vs. untreated at day 14) (K).
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2/2 =
26 days, n =5 ;P = 0.04 vs. untreated P2X7R
2/2; Fig. 5A).
To investigate the purinergic system function in P2X7R
2/2
mice, we analyzed the effect of benzoyl-ATP (Bz-ATP),
a synthetic agonist of the purinergic receptors, in CD4
+
and CD8
+ T cells. When 1 mmol/L Bz-ATP was added to
the cultured cells, IFN-g production increased in CD4
+
(Fig. 5B) and CD8
+ T cells (Fig. 5D) isolated from wild-
type mice. Bz-ATP similarly stimulated IFN-g production
from CD4
+ (Fig. 5C) and CD8
+ T cells (Fig. 5E) isolated
from P2X7R
2/2 mice. We hypothesized that compensatory
mechanisms may have arisen in P2X7R
2/2 mice, and in
particular, we investigated a possible upregulation of
P2X1R, P2X3R, and P2X4R, which also have been associ-
ated with the immune response (25). CD4
+ and CD8
+
T cells were extracted from wild-type and P2X7R
2/2 mice,
and the relative expression of P2XRs was assessed by real-
time PCR. Higher levels of P2X1R and P2X4R were found
FIG. 3. Histological analysis of islet allografts at day 14 after transplantation in untreated mice (hyperglycemic) revealed complete destruction of
the graft parenchyma (A) and absent insulin (E) and glucagon (F) staining, with diffuse inﬁltration primarily constituted by CD3
+ (B) and MAC2
+
(D) cells, with very few FoxP3
+ cells (C); conversely in oATP-treated mice (normoglycemic), islet allograft structure (G), and insulin (K) and
glucagon (L) staining were preserved, with mild inﬁltrate mainly conﬁned to the islet borders (H, J) with several FoxP3
+ cells (I) (representative
of different mice). Semi-quantiﬁcation of insulin staining conﬁrmed enhanced preservation of islet allografts in oATP-treated mice (n =5 ,* * P <
0.01 vs. untreated at day 14) (M), with no signiﬁcant differences in cell inﬁltrate (N). A reduction in Tbet (n =3 ,* P < 0.05 vs. untreated at day 14)
(O), but not of Rorc transcripts (P), was evident in islet allografts obtained from oATP-treated islet-transplanted mice compared with untreated
mice. Insulin (n = 5 for untreated and n = 10 for oATP-treated; **P < 0.01) (Q) and glucagon content (n = 5 for untreated and n = 6 for
oATP-treated; **P < 0.01) (R) resulted higher in transplanted islets harvested from oATP-treated compared with untreated recipients.
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2/2-derived CD4
+ T cells (P2X1R: 2-fold increase
vs. wild-type, n =3 ,P = 0.02; P2X4R: 1.7-fold increase vs.
wild-type, n =3 ,P = 0.03; Fig. 5F) and CD8
+ T cells
(P2X1R: 16-fold increase vs. wild-type, n =3 ,P = 0.003;
P2X4R: 1.3-fold increase vs. wild-type, n =3 ,P = 0.04;
Fig. 5G). Promotion of islet graft survival obtained by
oATP treatment also in P2X7R
2/2 recipients demonstrates
that the targeting of other purinergic receptors may con-
tribute to the immunomodulatory effects of oATP; how-
ever, some caution should be used when analyzing data
obtained from P2X7R
2/2 mice because compensatory
mechanisms in the purinergic system are present.
Rapamycin and P2XR7 targeting in vivo synergize in
reducing the alloimmune response. To evaluate a po-
tential clinically relevant protocol, we tested oATP com-
bined with a clinical-grade dose of rapamycin (oATP at
250 mg day 0 through day 15 + rapamycin at 0.1 mg/kg day
0 through day 10); ﬁve of seven islet-transplanted mice
t r e a t e dw i t ho A T P + r a p a m y c i ns h o w e dl o n g - t e r mg r a f tf u n c -
tion at 100 days after transplantation (MST: rapamycin = 18;
oATP+rapamycin = indeﬁnite, n = 7; oATP+rapamycin
vs. both untreated and rapamycin, P , 0.0001; oATP
+rapamycin vs. oATP, P = 0.04; Fig. 6A). Rapamycin was
more effective in prolonging islet graft survival in P2X7R
2/2
compared with wild-type recipients (n =7 ;P = 0.04 vs.
rapamycin in wild-type; Fig. 6A), conﬁrming the synergistic
effect between P2X7R-targeting and rapamycin. Better
protection of islet grafts was observed in wild-type recip-
ients treated with oATP+rapamycin than in P2X7R2/2
recipients treated with rapamycin alone (Fig. 6A), in-
dicating that the oATP may also target other purinergic
receptors. Pathology of islet allografts in long-term pro-
tected islet-transplanted oATP+rapamycin-treated mice
revealed preserved architecture (Fig. 6B) and maintained
insulin (Fig. 6F) and glucagon (Fig. 6G) staining. Islet in-
ﬁltrate was evident but appeared conﬁned to the border of
islet allografts (Figs. 6C and E) At higher magniﬁcations,
FoxP3
+ cells inﬁltrate appeared nearly as abundant as the
CD3
+ T-cell inﬁltrate, suggesting a high proportion of Tregs
(Fig. 6C and D, high-magniﬁcation insert). Mice treated
with short-course oATP+rapamycin were further pro-
tected from the alloimmune response, as demonstrated by
a decrease in the responsiveness toward donor alloantigen
and measured by the reduction in cells producing IFN-g
during ex vivo challenge with alloantigens (cells producing
IFN-g: oATP+rapamycin-treated at day 100 = 60 6 8 vs.
untreated at day 14, n =3 ,P , 0.0001; vs. oATP-treated
at day 14, n =3 ,P = 0.008; Fig. 6H). A parallel reduction in
FIG. 4. The effect of P2X7R targeting with oATP was tested in vitro. In an ELISPOT assay in which C57BL/6 splenocytes were challenged in vitro
with irradiated BALB/c splenocytes (Control), oATP treatment greatly reduced the number of cells producing IFN-g (n =5 ,* P < 0.05, ***P <
0.0001 vs. Control) (A), as well as increased the number of cells producing IL-4 (n =5 ,* P < 0.05 vs. Control) (B). C: oATP also inhibited the
proliferation of C57BL/6 splenocytes challenged with irradiated BALB/c splenocytes measured as incorporation of
3H-thymidine (n =5 ,* * * P <
0.0001 vs. Control). D: No signiﬁcant differences in the percentages of apoptotic cells (AnnexinV
+7-ADD
– cells) were evident in controls compared
with oATP-cultured splenocytes (representative of three different experiments). Luminex analysis of the supernatant showed reduced IFN-g (E),
IL-2 (F), IL-6 (G), and IL-17 (H) production in C57BL/6 splenocytes challenged with irradiated BALB/c splenocytes (n =5 ,* P < 0.05 vs. Control).
Conversely, targeting of P2X1R using the speciﬁc inhibitor NF 449 (I) or targeting of P2X3R using the speciﬁc inhibitor NF 110 (J) was unable to
modulate IFN-g production by C57BL/6 splenocytes challenged in an ELISPOT assay with irradiated BALB/c splenocytes. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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+ and CD8
+ effector cells was ob-
served in oATP+rapamycin-treated mice. The percentages
of peripheral CD4
+ effector T cells (Fig. 6I)a n dC D 8
+
effector T cells (Fig. 6J) were greatly reduced compared
with those observed in oATP-treated mice at day 14.
Stable levels of Th17 cells (Fig. 6K) and a slight de-
crease in the number of Tregs were observed in oATP
+rapamycin-treated mice (Fig. 6L). A better protection
of the islet graft structure was observed in rapamycin-
treated P2X7R
2/2 (Fig. 6S, W,a n dX) compared with
untreated P2X7R
2/2 recipients (Fig. 6M, Q,a n dR)a t
day 14 after transplantation. Immune cell inﬁltration
was reduced in rapamycin-treated P2X7R
2/2 recipients
(Fig. 6T, U,a n dV) compared with untreated P2X7R
2/2
recipients (Fig. 6N, O,a n dP).
P2X7R expression is increased in CD4
+ T cells
obtained from islet-transplanted patients. We then
sought to determine the P2X7R expression proﬁle in lym-
phocytes obtained from islet-transplanted patients to de-
termine the relevance of the P2X7R/ATP system in human
T cells and, potentially, in islet rejection in humans.
PBMCs from islet-transplanted patients, T1D patients, and
healthy control subjects were harvested, and CD4
+ T cells,
a key population in islet rejection, were analyzed by ﬂow
cytometry (Table 1). In healthy controls, the P2X7R
+CD4
+
T-cell population represented 17% of all PBMCs (Figs. 7A
and F), and P2X7R was expressed in almost 50% of pe-
ripheral CD4
+ T cells (data not shown). The percentage of
P2X7R
+CD4
+ T cells observed in recently well-functioning
transplanted patients (,3 years from last islet infusion)
were comparable to those of healthy control subjects
(Fig. 7A, C, and F). Conversely, the frequency of the
P2X7R
+CD4
+ T-cell population signiﬁcantly increased in
long-term islet-transplanted patients (.3 years; Fig. 7A, D,
and F) and in T1D patients (Figs 7A, B, and F). Among
CD4
+ T cells, an expansion of P2X7R
+CD45RO
+ cells
(T cells with a mature phenotype or memory T cells) was
observed in long-term islet-transplanted patients (Fig. 7G,
J,a n dL) and in T1D patients (Fig. 7G, H, and L) compared
with healthy control subjects. Conversely, a reduction in
naïve P2X7R
+CD45RA
+ cells (Fig. 7M, N, P,a n dR)w a s
observed. These data demonstrate a similar P2X7R ex-
pression pattern on CD4
+ T cells in long-term islet-
transplanted patients and in T1D patients, whereas a
different pattern is expressed on recently islet-transplanted
patients and healthy control subjects.
FIG. 5. A: A signiﬁcant prolongation of islet allograft survival was shown in P2X7R
2/2 C57BL/6 recipients of allogeneic BALB/c islets compared
with wild-type recipients (n = 10, ***P < 0.0001 vs. wild-type untreated), and oATP treatment prolonged islet graft survival in P2X7R
2/2 recipients
(n =5 ,§ P < 0.05 vs. P2X7R
2/2 untreated; ***P < 0.0001 vs. wild-type untreated). CD4
+ and CD8
+ T cells puriﬁed from splenocytes of wild-type
(B and D, respectively) or P2X7R
2/2 (C and E, respectively) C57BL/6 mice were challenged with anti-CD3 Ig and anti-CD28 Ig in the presence or
absence of different concentrations of Bz-ATP and were tested for IFN-g production in an ELISPOT assay. A preserved and efﬁcient Bz-ATP
response, despite the absence of P2X7R, was evident in P2X7R
2/2 mice (C and E) and in wild-type mice (B and D)( n =5 ,* P < 0.05, **P < 0.01 vs.
Control). CD4
+ T cells and CD8
+ T cells were extracted from wild-type and P2X7R
2/2 mice and were assessed for P2XRs expression. Higher levels
of P2X1R and P2X4R were observed in P2X7R
2/2 CD4
+ (F) and CD8
+ (G) T cells (n =3 ,* P < 0.05, **P < 0.01 vs. wild-type) compared with
wild-type.
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inhibits the alloimmune response in vitro. To conﬁrm
the immunomodulatory effect of P2X7R inhibition, we chal-
lenged PBMCs obtained from healthy control subjects with
allogeneic irradiated PBMCs obtained from different donors
in an ELISPOT assay in the presence of different concen-
trations of the human-speciﬁc P2X7R antagonist CE-224535,
which has been investigated in clinical trials for rheumatoid
arthritis. A reduction in the number cells producing IFN-g
was observed with CE-224535 treatment at 100 mmol/L
(29 6 1 vs. control 51 6 3, n =5 ,P =0 . 0 0 3 ;F i g .7 S).
DISCUSSION
Successful islet transplantation can improve metabolic
control and can reestablish normoglycemia in subjects
with T1D (3). Unfortunately, transplanted islets are sub-
jected to the damaging effects of the alloimmune response
and the recurrence of autoimmunity (20% of the patients
insulin-free at 5 years) (3,7,8,40). The better outcomes of
autologous islet transplantation from patients with chronic
pancreatitis (47% insulin-free at 5 years) (41), in whom the
allo- and autoimmune responses are absent, conﬁrms the
primary role of immune response in islet graft failure,
FIG. 6. A: In a clinically relevant combination, low-dose rapamycin treatment signiﬁcantly prolonged islet graft survival and synergized with oATP
treatment in promoting long-term islet graft survival in BALB/c islet allografts transplanted into hyperglycemic C57BL/6 mice (***P < 0.0001 vs.
untreated: §P < 0.05 vs. oATP-treated and rapamycin), and rapamycin was more effective in prolonging graft survival in P2X7R
2/2 than in wild-type
recipients (n =7 ;# P < 0.05 vs. rapamycin-treated wild-type). Histological analysis of graft islets at day 100 after transplantation in oATP+
rapamycin-treated mice revealed preserved islet structure (B) and insulin (F) and glucagon production (G) with mild extraislet T-cell (C) and
macrophage inﬁltration (E) as well as substantial Treg numbers (D). Splenocytes obtained from oATP+rapamycin-treated islet-transplanted mice
at day 100 displayed a lower number of cells producing IFN-g compared with untreated or oATP-treated mice at day 14 when challenged with
irradiated donor splenocytes (n = 3, ***P < 0.0001 vs. untreated; §§P < 0.01 vs. oATP-treated) (H). The percentages of CD4
+ effector T cells at day
14 (n =3 ,* P < 0.05 vs. untreated; §P < 0.05 vs. oATP-treated) (I) and CD8
+ effector T cells at day 14 (n =3 ,* P < 0.05, ***P < 0.0001 vs. un-
treated) (J) were also reduced. No differences in the number of Th17 cells were observed at day 14 (n =3 ,* P < 0.05 vs. untreated) (K), whereas
a slight reduction was seen in the percentage of Tregs (n =3 ,* P < 0.05 vs. untreated) (L) when rapamycin was added to the treatment protocol.
A better protection of the islet graft structure was observed in rapamycin-treated P2X7R
2/2 (S, W, and X) compared with untreated P2X7R
2/2
recipients (M, Q, and R) at day 14 after transplantation. Immune cell inﬁltration was reduced in rapamycin-treated P2X7R
2/2 recipients (T, U, and
V) compared with untreated P2X7R
2/2 recipients (N, O, and P). H&E, hematoxylin and eosin.
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islet graft loss (3). Considering the potential advantages of
islet transplantation in diabetes complications and the
relatively low invasiveness of the procedure, additional
research is required to develop novel strategies to lessen
the need for lifelong immunosuppression (42).
We studied the role of the ionotropic purinergic P2X
receptors in islet allograft rejection, particularly in light of
recent studies that have demonstrated roles for the ATP/
P2XR system in T-cell activation and in Th1/Th17-cell
generation (24–26). P2X7R may represent a crossroads for
naïve T cells to become activated during the alloimmune
response. Our data show that the expression of P2X1R and
P2X7R is higher in the islet allograft during rejection,
whereas in the syngeneic setting, only P2X1R has higher
expression. These data seem to link P2X7R expression
speciﬁcally to the alloimmune response, whereas P2X1R
expression appears to be more related to ischemia/reper-
fusion and peritransplant inﬂammation.
In our model of islet allotransplantation, P2X7R target-
ing with oATP was able to promote long-term graft func-
tion in 30% of recipients, and this effect was associated
with an extensive reshaping of the immune system,
speciﬁcally in a reduction of the anti-islet Th1 response,
a reduction in CD4
+ T effector and Th17 cells, which are
well known to promote the alloimmune response (29), and
a preservation of Tregs, which, on the contrary, promote
graft acceptance (43). Of particular interest in the clinical
setting is the synergistic effect observed between rapa-
mycin, which is a pivotal drug in clinical islet trans-
plantation (44), and oATP. This combination treatment
resulted in a preponderance of islet-transplanted mice
accepting a fully major histocompatibility complex–
mismatched allograft long-term, with hyporesponsive-
ness toward alloantigen and preservation of islet graft
morphology and insulin staining.
Although oATP is described as one of the most effective
P2X7R inhibitors in vivo (45,46), the targeting of P2X7R
with oATP has also been associated with the targeting of
other purinergic receptors (22). Our data in P2X7R
2/2
recipients conﬁrmed the presence of additional targets for
oATP, and this targeting appears beneﬁcial in the context
of allogeneic islet transplantation providing additional
immunomodulation. In particular, our data suggest that the
effect could be mediated by P2X1R targeting, which is
upregulated in the syngeneic and allogeneic graft and in
FIG. 7. PBMCs from healthy control subjects, T1D patients, and islet-transplanted patients were harvested and analyzed by ﬂow cytometry for
P2X7 expression. A higher percentage of P2X7
+CD4
+ T cells was evident in T1D patients and in long-term islet-transplanted patients (>3 years, n =
8) compared with recently islet-transplanted (<3 years, n = 8) or healthy control subjects (n =8 ;* * P < 0.01, ***P < 0.0001 vs. healthy controls and
recently islet-transplanted patients) (A, B, C, D,a n dF). Within the CD4
+ T-cell population, an increase in the percentage of memory
P2X7R
+CD45RO
+ cells was observed in T1D patients and in long-term islet-transplanted patients (**P < 0.01, ***P < 0.0001 vs. healthy controls
and recently islet-transplanted; §§P < 0.01 vs. healthy controls) (G, H, I, J,a n dL). Conversely, a reduction in the percentage of naïve
P2X7R
+CD45RA
+ cells was observed in T1D patients and in long-term islet-transplanted patients (***P < 0.0001 vs. healthy controls and recently
islet-transplanted; §P < 0.05 vs. healthy volunteers) (M, N, O, P, R). S: The targeting of P2X7R using the speciﬁc human inhibitor CE-224535 in an
ELISPOT assay in which human PBMCs were challenged with allogeneic human PBMC reduced the number of cells producing IFN-g (n =5 ,* * P <
0.01 vs. control).
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+ and CD8
+ T cells obtained from P2X7R
2/2 mice.
However, some caution should be used during analysis of
data using P2X7R
2/2 recipients; in these mice, the immu-
nological function of the other P2XRs may in fact become
more relevant, as suggested by the preserved response to
Bz-ATP in P2X7R
2/2-derived lymphocytes, accompanied
by the upregulation of other P2XRs. Further development
of speciﬁc antagonists for the different P2XRs suitable for
in vivo use (22,46) will help us to better dissect the relative
contribution of the targeting various P2XRs in islet graft
rejection.
In vitro, the targeting of P2X7R with oATP during
allostimulation inhibited the production of Th1/Th17
cytokines and T-cell activation, conﬁrming that P2X7R
signaling is required to trigger the Th1/Th17 immune re-
sponse (21,25); on the contrary, the expansion of Tregs is
not evident in our model, although this has been reported
in other settings (30).
By studying PBMCs obtained from different popula-
tions of human subjects, we were able to evaluate the
expression of P2X7R in different lymphocyte subsets The
P2X7R
+CD4
+ T-cell population appeared to be upregulated
in T1D patients and islet-transplanted patients in the long-
term, suggesting a link between activation of the immune
system, the anti-islet response, and expression of P2X7R.
Interestingly, an increase in memory and decrease of naïve
CD4
+ T-cells expressing P2X7R was observed in long-term
islet-transplanted recipients. Considering that progressive
loss of islet graft functio nm a yb ea s s o c i a t e dw i t ha
mounting of memory allo- and autoimmune cell respon-
ses (40,47), identifying potential new targets for the
memory-cell subpopulation is highly desirable. In this
sense, the targeting of P2X7R may represent a viable
option, particularly in light of the availability of clinical-
grade therapeutics, such as the human-speciﬁc inhibitor
CE-224535.
In conclusion, P2X7R-mediated alloimmunity is an im-
portant pathway in the alloimmune response that con-
tributes to priming of Th1/Th17 effector cells. Targeting of
P2X7R may thus be beneﬁcial in preventing islet allograft
rejection and inducing tolerance, thereby reducing the
need for immunosuppressive agents. Indeed, complete
tolerance induction may require a speciﬁc P2X7R-targeting
approach to abrogate Th1/Th17 alloimmunity and to fa-
cilitate a Treg sparing/expansion strategy. In view of the
novel anti-P2X7R inhibitors available for clinical use (e.g.,
CE-224535, AZD9056, and GSK1482160), our data may
have signiﬁcant clinical relevance for the ﬁeld of islet
transplantation.
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